Colorectal cancer (CRC), accounting for approximately 10% of all cancer cases, is one of the most common types of malignant tumor, leading to more than one-third of rectal-related incidences. Although several studies have revealed that environmental and genetic factors contribute to the occurrence and development of CRC, many mutations are detected in CRC, which play important roles in tumorigenesis and progression of the tumor. Studies have revealed that many genes were frequently mutated in CRC, including TP53, APC, KRAS, PIK3CA, NRAS, FBXW7, SMAD4 and TCF7L2. Interestingly, we found that PTPN4 negative cytoplasm staining was more prone to lymphatic metastasis (N = 50, P = 0.0153) and low expression of PTPN4 in rectal cancer was highly associated with poor prognosis. Overexpression of PTPN4 suppressed the cell growth, and moreover, the loss of PTPN4 accelerated cell growth and boosted clonogenicity of CRC cells. Furthermore, we revealed that the deletion of PTPN4 promoted the tumor formation of NCM460 cells in vivo. In terms of the molecular mechanism, we demonstrated that PTPN4 dephosphorylates pSTAT3 at the Tyr705 residue with a direct interaction and suppresses the transcriptional activity of STAT3. In summary, our study revealed a novel mechanism that the tumorigenesis of colorectal cancer might be caused by the loss of PTPN4 through activating STAT3, which will broaden the therapy strategy for anti-rectal cancer in the future.
JNK, NF-κB, Wnt and PTEN/PI3K/AKT, controlled by protein tyrosine kinases and protein tyrosine phosphatases (PTP). 2 In human beings, there are more than 100 phosphatases genes, 3 which can be divided into 4 distinct classes according to amino acid sequence in the phosphatase catalytic domains. Among these phosphatases, the largest class, Class I, can be divided into receptor and non-receptor PTP.
3 PTPN4/PTP-MEG1, a widely expressed non-receptor PTP, contains FERM, PDZ and C-terminal catalytic domains. In 1991, PTPN4 gene was first cloned with a human megakaryoblastic cell line (MEG-01) and umbilical vein endothelial cell cDNA libraries, which is the reason that PTPN4 was also referenced as MEG: PTPMEG or PTPMEG1. 4 PTPN4 localizes in the cytoplasm and the plasma membrane. The active form of PTPN4 consists of the PDZ and PTP domains. 5 Emerging studies have shown that PTPN4 participates in many biological processes. The overexpression of PTPN4 affects cell growth and colony formation in soft agar of COS-7 cells and suppresses CrkImediated cell growth and mobility in HEK293T cells. 6, 7 However, other studies have addressed that PTPN4 suppresses the cell apoptosis of neuroblastoma and glioblastoma cell lines in a PDZ-PDZ binding motifs-dependent manner. Besides the regulation of cell proliferation and apoptosis, PTPN4 also plays an important part in innate immune responses by suppressing tyrosine phosphorylation of TRAM and the TCR ITAM. Moreover, other studies have suggested that PTPN4 was highly associated with learning, spatial memory and cerebellar synaptic plasticity. 8, 9 In these studies, 5 endogenous partners of PTPN4 have been reported: (i) mitogen-activated protein kinase (MAPK) p38γ; (ii) glutamate receptor δ2 and ε subunits; (iii) TRIF-related adaptor molecule TRAM; (iv) T-cell receptor ξ subunit; and (v) oncoprotein CrkI.
However, it remains unclear whether PTPN4 participates in the CRC tumorigenesis and the detailed mechanism of PTPN4 regulation in CRC still needs to be elucidated.
In this study, we identified a nonsense mutation of PTPN4 from 1 case of rectal cancer by exome capture DNA sequencing, leading to loss of function in PTPN4 gene. Low expression of PTPN4 in rectal cancer is associated with poor prognosis, and overexpression of PTPN4 suppresses the cell growth of colorectal cancer cells.
Moreover, the deletion of PTPN4 promotes the cell proliferation ability and tumor formation of colorectal cancer cells. In terms of molecular mechanisms, we revealed that PTPN4 dephosphorylates pSTAT3 at the Tyr705 residue with a direct interaction, which might provide novel targets for the therapy of CRC.
| MATERIAL S AND ME THODS

| Cell culture, antibodies and plasmid construction
DLD-1, NCM460 (one immortalized colorectal epithelial cell line) and HEK293T cells were obtained from ATCC and maintained in our laboratory according to the recommendation of ATCC. Stable cell lines for the knockdown of PTPN4 by shRNA were generated based on DLD-1, which were infected with lentivirus and selected by puromycin at 2 μg/mL. Stable cell line for knockout of PTPN4 by CRISPR Case9 was generated based on NCM460
and screened using FACS. The guide RNA used for knocking out of PTPN4 were 5′-TCTAGACAAATCAGCTTGAA-3′ and 5′-GGTTACGACCATCTTCAGTT-3′, which were selected from http:// crispr.mit.edu/ and subcloned into the PX458M plasmid.
Anti-PTPN4 antibody was purchased from Sigma-Aldrich (St.
Louis, MO, USA) (HPA019351) and Abcam (Cambridge, MA, USA) (ab200363). Anti-phosphotyrosine antibody (4G10) was purchased from Millipore (Hong Kong, China). Anti-HA, anti-Erk1/2, antipErk1/2 and protein G/A plus agarose beads were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-pSTAT3 (Tyr705), anti-pSTAT3 (Ser727), anti-STAT3, anti-Ki-67, anti-β-Actin antibodies and anti-rabbit IgG (H+L), F(ab′)2 Fragment was purchased from Cell Signaling Technology (Shanghai, China). Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 546 was purchased from Thermo Fisher Scientific (Shanghai, China).
Plasmids including 3Flag-PTPN4 and 3HA-PTPN4-IRES-EGFP were expression vectors constructed based on pcDNA3.0-3Flag and pCDH-CAG-3HA-IRES-EGFP, respectively, for human PTPN4 and PTPN4 c.549dupT.
| Clinical samples
Eleven primary paired rectal cancer samples including tumor and adjacent non-tumorous samples were randomly selected from the Chinese PLA General Hospital (Beijing) and used for the western blot. The pathological type was confirmed by the pathologists. 
| Immunohistochemical staining
Formalin-fixed, paraffin-embedded tissue blocks were cut into 4-μm paraffin sections, followed by immunohistochemical analysis. The slides were heated in a tissue-drying oven for 40 minutes at 65°C, 
| Western blotting
Cells were harvested and homogenized in RIPA buffer (Cell Signaling Technology, Shanghai, China), followed by determination of protein concentration using the BCA Kit (Life Technologies, Shanghai, China). Proteins were resolved by 10% SDSPAGE, and then trans- 
| RT-PCR
The primers used for PTPN4 amplification were 5′-ATCTCCACC Triton X-100, 1 μg/mL DAPI) and incubated at room temperature for 30 minutes. Each sample was tested for 30 000 cells by flow cytometry.
| Luciferase assay
HEK293T cells were plated in 24-well plates the day before transfection. A total of .05 μg pAPRE-luc or .1 μg pFA-luc plus .1 μg pFR-ELK1
reporter plasmid together with 5 ng of pRL-TK was transfected. The constructed plasmid overexpressing PTPN4 was co-transfected at an amount of .4 μg/well. Four hours after transfection, HEK293T cells were treated with EGF (25 ng/mL) for 6 hours after starvation for 24 hours, and luciferase assays were conducted with a dual-luciferase reporter assay system (Vigofect, Beijing, China).
| Colony formation assay
Cells were plated in 6-well plates at a density of 500 or 1000 cells/well.
After culturing for 10 days, cells were fixed with methanol for 10 minutes and incubated with .1% crystal violet (Sigma) for 10 minutes at room temperature. The number of colonies was counted by Image J. 
| Tumorigenesis assay
| Immunoprecipitation assay
Lysates were subjected directly to immunoblot analysis and immu- 
| The construction of lentivirus plasmids
Short hairpin RNA (shRNA) was designed to downregulate PTPN4.
The sequences were: 5′-GCTCCGAACAAATAGTAAATA-3′ (PTPN4-
CGTCATCAACACAAGCTAATA-3′ (PTPN4-shRNA8). Then, the sequences were inserted into pCDH-GLI-1-shRNA plasmids.
| Statistical analysis
Data were represented as mean ± SD. Significant differences between proportions were assessed using Fisher's exact test.
Significant differences between 2 groups were determined using Student's t test. Significant differences between 3 groups were determined using one-way ANOVA. Survival analysis was performed using Kaplan-Meier method. All the analyses were conducted using SPSS 17.0 software. Statistical significance was defined as P < 0.05.
| RE SULTS
| A nonsense mutation of PTPN4 is detected in 1 case of rectal cancer
A 47-year-old Chinese man, who was categorized as T4bN2aM1
stage IV in the NCCN guideline and diagnosed as having moderately-poorly differentiated adenosquamous carcinoma pathologically, underwent palliative resection for rectal cancer ( Figure 1A ).
Whole-exome capture DNA sequencing was performed on the patient's tumor and leukocyte before PD-1 inhibitor treatment.
After 3 months of treatment, the patient died of tumor progression.
Surprisingly, a total of 98 somatic mutated genes were identified in the tumor tissue from the patient. Among these genes, a c.549dupT
mutation of PTPN4 was identified with the highest mutation ratio of 90.90% ( Figure 1B , Table S1 ). The mutation ratio exceeded 50%, so PTPN4 c.549dupT was a biallelic mutation. In consideration of the mutation ratio of 90.90%, the mutation of PTPN4 might occur in the early stage of tumorigenesis. A further sequence analysis demonstrated that this mutation enabled PTPN4 to obtain a premature stop codon, which was a kind of nonsense mutation. As a conse- . Taken together, all these data F I G U R E 1 A nonsense mutation of PTPN4 is identified in 1 case of rectal cancer. A, Computer tomography image of abdomen and pelvic cavity. Tumor (red triangle) thickened rectal wall (right side) and dilated the abdominal intestines (left side). B, PTPN4 had a mutation with the highest mutation ratio. A total of 98 somatic mutated genes were identified in 1 case of rectal cancer by exome capture DNA sequencing. C, A c.549dupT mutation enabled PTPN4 to obtain a premature stop codon. D, The molecular weight of wild PTPN4 encoded by 3Flag-PTPN4 is >100 kDa, while protein encoded by 3Flag-PTPN4 c.549dupT is <30 kDa. E, The expression of PTPN4 was negative in the rectal tumor tissue, whereas the positive PTPN4 was observed in the paired adjacent normal tissue. F, Several somatic mutations of PTPN4 were found in rectal cancer samples from the TCGA READ database. Somatic mutations in PTPN4 occur mainly in patients with heavy tumor burden suggested that c.549dupT in PTPN4, a nonsense mutation with a mutation ratio of 90.90%, occurring in colorectal cancer, may play an essential role in the early stage of CRC tumorigenesis.
| Low expression of PTPN4 is associated with poor prognosis in rectal cancer
To explore the role of PTPN4 in the tumorigenesis and development of colorectal cancer, we evaluated the expression of PTPN4 in 11 primary rectal cancer tissues compared with their adjacent normal tissues by western blot. None of the patients received neoadjuvant therapy.
Approximately 27% (3 in 11 samples) of primary rectal cancer tissues showed a significant downregulation of PTPN4, while around 36% (4 in 11 samples) of the primary rectal cancer tissues exhibited high expression of PTPN4 compared with their adjacent normal tissues (Figure 2A ).
It has been reported that lymph node metastasis is associated with poor prognosis. 10 In our study, although there is no significant differ- (High) and bottom 25% (Low) patients, no significant correlation was observed between PTPN4 expression and gender, age, and the TNM stage of rectal cancer patients (Table S2) . However, the Kaplan-Meier analysis showed that a low level of PTPN4 mRNA was associated with a poor overall survival rate ( Figure 2G ). All these results indicated that PTPN4 may not be a driver gene in most rectal cancers. However, low expression of PTPN4 in rectal cancer is associated with poor prognosis.
| PTPN4 suppresses the proliferation ability of colorectal cancer cells
To explore the function of PTPN4 in CRC, we examined the ef- Figure 3R ). Taken together, F I G U R E 2 Low expression of PTPN4 is associated with poor prognosis in rectal cancer. A, Approximately 27% (3 in 11 samples) of primary rectal cancer tissues showed a significant downregulation of PTPN4, while approximately 36% (4 in 11 samples) of the primary rectal cancer tissues exhibited high expression of PTPN4, compared with their adjacent normal tissues. A western blot assay was used to detect the PTPN4 protein level and PCNA was used to indicate the tumor tissues. GAPDH was used as a loading control. B, Patients with downregulated expression of PTPN4 (blue color) had more metastatic nodes. C, Immunohistochemical staining detected PTPN4 expression in tumor tissues of patients with stage II and III rectal cancer. 1: PTPN4 negative staining; 2: PTPN4 weak staining; 3: PTPN4 moderate staining; 4: More abundant expression of PTPN4 was observed in well-differentiated tumor tissue compared to poorly differentiated tumor tissue in the same slide. D, Patients with PTPN4 negative cytoplasm staining were more prone to lymphatic metastasis (P = 0.0153). E, The mRNA level of PTPN4 in tumors was remarkably increased compared with their paired adjacent normal tissues. Data were from the TCGA READ cohort and a paired Student's t test was used to analyze the statistical significance between the tumor tissues and the paired normal tissues (P = 0.0277). F, The mRNA level of PTPN4 was significantly increased in tumor tissues compared with normal tissues. Data were from the TCGA READ cohort and a Student's t test analysis was used to examine the significance between the tumor and the normal tissues.
(P = 0.0015). G, The low expression of PTPN4 is associated with poor overall survival in rectal cancer. Data were from TCGA database, Rectal cancer patients were ranked according to PTPN4 mRNA level. The top 25% (High) and bottom 25% (Low) of patients were kept. Kaplan-Meier analysis was used to examine the survival rate (P = 0.014)
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all these results lead us to the conclusion that PTPN4 suppresses the proliferation ability and tumorigenesis of colorectal cancer cells.
| Expression of PTPN4 correlates with cell cycle progression
Moreover, a FACS analysis was conducted to determine whether PTPN4 alters the cell cycle. Our cell cycle analysis clearly demonstrated that exogenous expression of PTPN4 shortened the S phase and prolonged the G1 phase in HEK293T cells ( Figure 4A,B) . 
| PTPN4 suppresses the transcription activities of STAT3 and Erk1/2 by impairing the levels of pSTAT3 (705) and pErk
Many studies have reported that PTPN4 is a PTP. To address the function of PTPN4 on overall state of protein tyrosine phosphorylation, we transfected HEK293T cells with 3HA-PTPN4 and conducted immunoprecipitation experiments. Overexpression of PTPN4 did not result in detectable changes in the overall state of protein tyrosine phosphorylation in lysate and co-immunoprecipitation product ( Figure 4A ). Previous studies showed that the endogenous PTPN4 only accounts for approximately 1/3000th of the total tyrosine phosphatase activity in COS-7 cells. 6 These results illustrated that the effect of PTPN4 on cell proliferation is likely via specific substrates rather than global dephosphorylation.
Previously, our laboratory demonstrated that PTPMeg2 directly mediates the dephosphorylation of pSTAT3 and negatively regulates STAT3 activity. 11 In other studies, PTPN2, PTPN3, PTPN5, PTPN7 and PTPN11 were reported to act on kinases upstream or downstream in EGF receptor-mediated signaling pathway. Therefore, we examined whether PTPN4 dephosphorylates STAT3 and Erk1/2. The results
showed that the level of pSTAT3 (705) 
| D ISCUSS I ON
Most CRC occurs sporadically due to genetic mutations and epigenetic modifications of the human genome. 12 These genetic mutations and epigenetic modifications promote the conversion from Product of the wild-type form of these genes depresses the growth of colorectal cancer cells. 15 Mutations leading to loss of function in non-receptor PTPs, including PTPN3, PTPN13 and PTPN14, were identified in several human cancers (including gastric, lung, breast and colorectal cancer). However, whether PTPN genes are responsible for the development of colorectal cancer still needs to be explored and the detailed mechanism remains to be elucidated.
In our study, we identified a nonsense mutation of PTPN4 from 1 case of rectal cancer with a mutation ratio of 90.90%. The mutation ratio exceeded 50%, so PTPN4 c.549dupT was a biallelic mutation. which is similar to the report of loss of activity of PTPN13 through somatic mutations in some tumors. 16 The ratio of 90.90% indicated Meanwhile, the cell cycle analysis by FACS indicated that the G1 phase was shortened and the S phase was prolonged when PTPN4
was deleted in NCM460 cells, leading to elevated cell cycle process.
These results imply that loss of PTPN4 promoting the cell viability might be through the alteration of the cell cycle. However, understanding the detailed signal pathways of PTPN4 involved into the cell cycle requires further study.
In terms of the molecular mechanism, we found that PTPN4 is a tumor repressor dephosphorylating pSTAT3 at residue Tyr705 but not Ser727, leading to suppressed transcriptional activity of STAT3.
Hyperphosphorylation of STAT3 at residue Tyr705 is associated with different kinds of human cancers. 17 Phosphorylated STAT3 dimerizes and accumulates in the nucleus, where it activates the transcription of a series of genes, including c-Myc and cyclin D1. 18 Loss of PTPN4 leads to the hyperactivation of STAT3 signaling pathway and promotes tumorigenesis. Interestingly, we also found that PTPN4 interacted with STAT3 and did not interact with STAT3 (Tyr705F) in vitro ( Figure 5D ). However, even though the decreased phosphorylation of Erk was observed in PTPN4 overexpressed cells ( Figure 5B,C) , the interaction between PTPN4 and Erk1/2 could not be examined.
Moreover, we found that the phosphorylation level of Erk1/2 was scarcely changed in the PTPN4-deleted NCM460 cells when EGF was withdrawn after stimulation for 5 minutes, while pSTAT3 remained significantly stronger at the same time in a cytokine additionwithdrawal assay ( Figure 5H ). Nevertheless, the overexpression of PTPN4 resulted in a decrease of the transcriptional activity of Erk1/2 in response to stimulation of EGF ( Figure 5G ). We hypothesize that the regulation of PTPN4 on Erk may be through other factors in an indirect manner, which remains to be explored in the future. Although we have demonstrated that PTPN4 participated in the regulation of F I G U R E 5 PTPN4 suppresses the transcription activities of STAT3 and Erk by impairing the levels of pSTAT3 and pErk. A, No detectable changes of the tyrosine phosphorylation were observed for the overall state of proteins in PTPN4 overexpressed HEK293T cells compared with the control group. 3HA-PTPN4 was transfected into HEK293T cells and immunoprecipitation (IP) was performed using an antibody against HA after 24 h of transfection. The precipitation complex was examined bywestern blot using an antibody against HA (left) or anti-phosphotyrosine antibody (4G10) (right). The tyrosine phosphorylation of total cell lysate was detected by western blot with a 4G10 antibody (right, the first and second lanes). (B) PTPN4 robustly suppresses the phosphorylation level of pSTAT3 (Tyr705) and pErk1/2 with or without epidermal growth factor (EGF; 25 ng/mL) treatment for 5 min in a dose-dependent manner. Different amounts of 3HA-PTPN4 were transfected into HEK293T cells and western blot was performed with the indicated antibodies. β-actin was used as a loading control. (C) Wild-type, but not the truncated, PTPN4 suppresses the phosphorylation of pSTAT3 (Tyr705) and pErk1/2 in the presence of EGF (25 ng/ mL) for 5 min. The 3Flag-PTPN4 and 3Flag-PTPN4 c.549dupt were transfected into HEK293T cells and levels of pSTAT3 (Tyr705), pSTAT3
(Ser727) and pErk1/2 were examined with western blot in the presence of EGF (25 ng/mL) for 5 min. (D) PTPN4 specifically interacts with STAT3 in vitro. Flag-STAT3 and 3HA-PTPN4 (or Flag-STAT3 (Tyr705F) and 3HA-PTPN4) were transfected into HEK293T cells and harvested for the precipitation after 24-36 h. Immunoprecipitation (IP) was performed using an antibody against Flag or HA. The complex was examined by a western blot using antibody against Flag and HA. The lysate and precipitated complex were examined by a western blot using antibodies against HA and Flag. E, PTPN4 co-localizes with STAT3 in the cytoplasm. HEK293T cells expressing 3Flag-PTPN4 were stained with an anti-Flag (red) and STAT3 (green) antibody. The images were viewed with a confocal microscope. Colocalization of 3Flag-PTPN4 and STAT3 in the cytoplasm is shown as yellow. F, PTPN4 abrogates the inducible transcriptional activity of STAT3 treated with EGF. Luciferase assays were performed using HEK293T cells with transient expression of 3HA-PTPN4 with APRE-Luc. The pRL-TK was used as an internal control. G, PTPN4 inhibits EGF-stimulated transcriptional activity of Erk1/2. The 3HA-PTPN4 was co-transfected with pFA-luc and pFR-ELK1 plasmids into HEK293T cells for the luciferase experiment. The pRL-TK was used as an internal control. Student's t test was used for the significance analysis for the luciferase assay. ***P < 0.001. Results are showed as mean ± SD from 3 independent experiments. H, Deletion of PTPN4 impairs the dephosphorylation of pSTAT3 and pErk1/2. Wild-type PTPN4 (PTPN4 WT ) and PTPN4 knockout (PTPN4  KO ) NCM460 cells were treated with EGF (25 ng/mL) for 5 min, followed by releasing into serum-free medium for the indicated times. The cell lysate was detected by anti-pSTAT3 (Tyr705) and anti-pErk1/2 antibodies with western blot and the β-actin was used as a loading control. (I) Immunofluorescence staining showed that STAT3 stayed longer in the nucleus in PTPN4 KO NCM460 cells. Wild-type PTPN4 (PTPN4 WT ) and PTPN4 knockout (PTPN4 KO ) NCM460 cells were treated with EGF (25 ng/mL) for 5 min, followed by releasing into serum-free medium for indicated times. Then cells were fixed with 4% paraformaldehyde for 20 min and perforated with .3% Triton X-100 for 10 min. After blocking with 10% FBS for 50 min, cells were incubated with anti-STAT3 antibody overnight at 4°C, followed with incubation with the second antibody coupled with green fluorescence, then stained with DAPI
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STAT3 and Erk, we cannot exclude the possibility that PTPN4 may target other substances, based on the fact that PTPN4 was shown to participate in many biological processes.
Currently, whole-exome sequencing and integrative analysis of genomic data provide insight into the pathways that are dysregulated in CRC. Most studies focus on somatic mutation frequencies in the population. However, the mutation ratio in 1 sample can also provide a lot of information about the function of somatic mutation on tumorigenesis and tumor progression. In our study, we identified that a nonsense mutation of PTPN4 resulted in a loss of function for the wild-type gene and revealed the mechanism that deletion of PTPN4 promotes the cell proliferation and tumorigenesis in CRC through the regulation of pSTAT3 and pErk, which might be a novel target for the therapy of CRC.
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